Cancer immunotherapy in veterinary medicine: Current options and new developments

Veterinary Journal

Volumn 207, Issue , 2016, Pages 20-28

  Regan, Daniel ^a   Guth, Amanda ^a   Coy, Jonathan ^a   Dow, Steven ^a  

^a Veterinary Dentistry and Oral Surgery   (United States)

Author keywords

Antibody; Cancer; Dog; Immune system; Macrophage; T cell; Treatment

Indexed keywords

BCG VACCINE; CANCER VACCINE; CATIONIC LIPOSOME DNA COMPLEX; CHECKPOINT KINASE INHIBITOR; CHEMOKINE RECEPTOR CCR2 ANTAGONIST; CLODRONIC ACID; CORYNEBACTERIUM PARVUM VACCINE; DENDRITIC CELL VACCINE; HEAT SHOCK PROTEIN 70; IMIQUIMOD; IMMUNOLIPOSOME; INTERLEUKIN 12; IPILIMUMAB; LYMPHOMA VACCINE; MELANOMA VACCINE; MIFAMURTIDE; MONOCYTE CHEMOTACTIC PROTEIN 1; MONOPHENOL MONOOXYGENASE; MURAMYL TRIPEPTIDE; NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN LIKE RECEPTOR; PEMBROLIZUMAB; PLACEBO; RECOMBINANT ALPHA INTERFERON; SIPULEUCEL T; TOCERANIB; TOLL LIKE RECEPTOR; TUMOR CELL VACCINE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN;

ANIMAL VENEREAL TUMOR; ANTINEOPLASTIC ACTIVITY; BREAST TUMOR; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CANINE CANCER; CD8+ T LYMPHOCYTE; CELL ACTIVATION; CELL ENGINEERING; CELL HOMING; CYTOKINE PRODUCTION; DISEASE FREE INTERVAL; DOG DISEASE; EFFECTOR CELL; HISTIOCYTIC SARCOMA; HUMAN; IMMUNOGENICITY; INNATE IMMUNITY; KIDNEY CARCINOMA; LYMPHOMA; MACROPHAGE; MELANOMA; MEMORY T LYMPHOCYTE; MENINGIOMA; METASTASIS; MONOCYTE; NATURAL KILLER CELL; NEOPLASM; NON SMALL CELL LUNG CANCER; NONHUMAN; OSTEOSARCOMA; OVERALL SURVIVAL; PROTEIN TARGETING; REVIEW; SOFT TISSUE SARCOMA; SURVIVAL TIME; T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR GROWTH; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; VETERINARY MEDICINE; ANIMAL; IMMUNOTHERAPY; NEOPLASMS; TRENDS; VETERINARY;

ANIMALS; IMMUNOTHERAPY; NEOPLASMS; VETERINARY MEDICINE;

EID: 84952888821     PISSN: 10900233     EISSN: 15322971     Source Type: Journal    
DOI: 10.1016/j.tvjl.2015.10.008     Document Type: Review

References (138)

1. Aldrich J.F., Lowe D.B., Shearer M.H., Winn R.E., Jumper C.A., Kennedy R.C. Vaccines and immunotherapeutics for the treatment of malignant disease. Clinical and Developmental Immunology 2010, 697158. 10.1155/2010/697158.
2. Allison J.P., Chambers C., Hurwitz A., Sullivan T., Boitel B., Fournier S., Brunner M., Krummel M. A role for CTLA-4-mediated inhibitory signals in peripheral T cell tolerance?. Novartis Foundation Symposium 1998, 215:92-98.
3. Andersen B.M., Pluhar G.E., Seiler C.E., Goulart M.R., SantaCruz K.S., Schutten M.M., Meints J.P., O'Sullivan M.G., Bentley R.T., Packer R.A., et al. Vaccination for invasive canine meningioma induces in situ production of antibodies capable of antibody-dependent cell-mediated cytotoxicity. Cancer Research 2013, 73:2987-2997.
4. Bergman P.J. Cancer immunotherapy. Topics in Companion Animal Medicine 2009, 24:130-136.
5. Bergman P.J., McKnight J., Novosad A., Charney S., Farrelly J., Craft D., Wulderk M., Jeffers Y., Sadelain M., Hohenhaus A.E., et al. Long-term survival of dogs with advanced malignant melanoma after DNA vaccination with xenogeneic human tyrosinase: A phase I trial. Clinical Cancer Research 2003, 9:1284-1290.
6. Biller B.J., Elmslie R.E., Burnett R.C., Avery A.C., Dow S.W. Use of FoxP3 expression to identify regulatory T cells in healthy dogs and dogs with cancer. Veterinary Immunology and Immunopathology 2007, 116:69-78.
7. Biller B.J., Guth A., Burton J.H., Dow S.W. Decreased ratio of CD8+ T cells to regulatory T cells associated with decreased survival in dogs with osteosarcoma. Journal of Veterinary Internal Medicine 2010, 24:1118-1123.
8. Bird R.C., Deinnocentes P., Church Bird A.E., van Ginkel F.W., Lindquist J., Smith B.F. An autologous dendritic cell canine mammary tumor hybrid-cell fusion vaccine. Cancer Immunology, Immunotherapy 2011, 60:87-97.
9. Buonaguro L., Petrizzo A., Tornesello M.L., Buonaguro F.M. Translating tumor antigens into cancer vaccines. Clinical and Vaccine Immunology 2011, 18:23-34.
10. Casucci M., Bondanza A., Falcone L., Provasi E., Magnani Z., Bonini C. Genetic engineering of T cells for the immunotherapy of haematological malignancies. Tissue Antigens 2012, 79:4-14.
11. Cheadle E.J., Gornall H., Baldan V., Hanson V., Hawkins R.E., Gilham D.E. CAR T cells: Driving the road from the laboratory to the clinic. Immunological Reviews 2014, 257:91-106.
12. Choi B.D., Cai M., Bigner D.D., Mehta A.I., Kuan C.T., Sampson J.H. Bispecific antibodies engage T cells for antitumor immunotherapy. Expert Opinion on Biological Therapy 2011, 11:843-853.
13. Chuang T.F., Lee S.C., Liao K.W., Hsiao Y.W., Lo C.H., Chiang B.L., Lin X.Z., Tao M.H., Chu R.M. Electroporation-mediated IL-12 gene therapy in a transplantable canine cancer model. International Journal of Cancer 2009, 125:698-707.
14. Cieri N., Mastaglio S., Oliveira G., Casucci M., Bondanza A., Bonini C. Adoptive immunotherapy with genetically modified lymphocytes in allogeneic stem cell transplantation. Immunological Reviews 2014, 257:165-180.
15. Condamine T., Gabrilovich D.I. Molecular mechanisms regulating myeloid-derived suppressor cell differentiation and function. Trends in Immunology 2011, 32:19-25.
16. Cruz C.R., Micklethwaite K.P., Savoldo B., Ramos C.A., Lam S., Ku S., Diouf O., Liu E., Barrett A.J., Ito S., et al. Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: A phase 1 study. Blood 2013, 122:2965-2973.
17. Dannull J., Haley N.R., Archer G., Nair S., Boczkowski D., Harper M., De Rosa N., Pickett N., Mosca P.J., Burchette J., et al. Melanoma immunotherapy using mature DCs expressing the constitutive proteasome. Journal of Clinical Investigation 2013, 123:3135-3145.
18. De Santo C., Serafini P., Marigo I., Dolcetti L., Bolla M., Del Soldato P., Melani C., Guiducci C., Colombo M.P., Iezzi M., et al. Nitroaspirin corrects immune dysfunction in tumor-bearing hosts and promotes tumor eradication by cancer vaccination. Proceedings of the National Academy of Sciences of the United States of America 2005, 102:4185-4190.
19. Denies S., Sanders N.N. Recent progress in canine tumor vaccination: Potential applications for human tumor vaccines. Expert Review of Vaccines 2012, 11:1375-1386.
20. Dolan D.E., Gupta S. PD-1 pathway inhibitors: Changing the landscape of cancer immunotherapy. Cancer Control: Journal of the Moffitt Cancer Center 2014, 21:231-237.
21. Dosset M., Godet Y., Vauchy C., Beziaud L., Lone Y.C., Sedlik C., Liard C., Levionnois E., Clerc B., Sandoval F., et al. Universal cancer peptide-based therapeutic vaccine breaks tolerance against telomerase and eradicates established tumor. Clinical Cancer Research 2012, 18:6284-6295.
22. Dow S., Elmslie R., Kurzman I., MacEwen G., Pericle F., Liggitt D. Phase I study of liposome-DNA complexes encoding the interleukin-2 gene in dogs with osteosarcoma lung metastases. Human Gene Therapy 2005, 16:937-946.
23. Dow S.W., Schwarze J., Heath T.D., Potter T.A., Gelfand E.W. Systemic and local interferon gamma gene delivery to the lungs for treatment of allergen-induced airway hyperresponsiveness in mice. Human Gene Therapy 1999, 10:1905-1914.
24. Duffy A., Dow S., Ogilvie G., Rao S., Hackett T. Hematologic improvement in dogs with parvovirus infection treated with recombinant canine granulocyte-colony stimulating factor. Journal of Veterinary Pharmacology and Therapeutics 2010, 33:352-356.
25. Forde P.M., Reiss K.A., Zeidan A.M., Brahmer J.R. What lies within: Novel strategies in immunotherapy for non-small cell lung cancer. The Oncologist 2013, 18:1203-1213.
26. Fourcade J., Sun Z., Benallaoua M., Guillaume P., Luescher I.F., Sander C., Kirkwood J.M., Kuchroo V., Zarour H.M. Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients. The Journal of Experimental Medicine 2010, 207:2175-2186.
27. Frankel S.R., Baeuerle P.A. Targeting T cells to tumor cells using bispecific antibodies. Current Opinion in Chemical Biology 2013, 17:385-392.
28. Fujiwara H. Adoptive T-cell therapy for hematological malignancies using T cells gene-modified to express tumor antigen-specific receptors. International Journal of Hematology 2014, 99:123-131.
29. Gabrilovich D. Mechanisms and functional significance of tumour-induced dendritic-cell defects. Nature Reviews. Immunology 2004, 4:941-952.
30. Gavazza A., Lubas G., Fridman A., Peruzzi D., Impellizeri J.A., Luberto L., Marra E., Roscilli G., Ciliberto G., Aurisicchio L. Safety and efficacy of a genetic vaccine targeting telomerase plus chemotherapy for the therapy of canine B-cell lymphoma. Human Gene Therapy 2013, 24:728-738.
31. Gill V.L., Bergman P.J., Baer K.E., Craft D., Leung C. Use of imiquimod 5% cream (Aldara) in cats with multicentric squamous cell carcinoma in situ: 12 Cases (2002-2005). Veterinary and Comparative Oncology 2008, 6:55-64.
32. Goubier A., Fuhrmann L., Forest L., Cachet N., Evrad-Blanchard M., Juillard V., Fischer L. Superiority of needle-free transdermal plasmid delivery for the induction of antigen-specific IFN gamma T cell responses in the dog. Vaccine 2008, 26:2186-2190.
33. Grosenbaugh D.A., Leard A.T., Bergman P.J., Klein M.K., Meleo K., Susaneck S., Hess P.R., Jankowski M.K., Jones P.D., Leibman N.F., et al. Safety and efficacy of a xenogeneic DNA vaccine encoding for human tyrosinase as adjunctive treatment for oral malignant melanoma in dogs following surgical excision of the primary tumor. American Journal of Veterinary Research 2011, 72:1631-1638.
34. Grosso J.F., Kelleher C.C., Harris T.J., Maris C.H., Hipkiss E.L., De Marzo A., Anders R., Netto G., Getnet D., Bruno T.C., et al. LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systems. The Journal of Clinical Investigation 2007, 117:3383-3392.
35. Guth A.M., Hafeman S.D., Dow S.W. Depletion of phagocytic myeloid cells triggers spontaneous T cell- and NK cell-dependent antitumor activity. Oncoimmunology 2012, 1:1248-1257.
36. Guth A.M., Hafeman S.D., Elmslie R.E., Dow S.W. Liposomal clodronate treatment for tumour macrophage depletion in dogs with soft-tissue sarcoma. Veterinary and Comparative Oncology 2013, 11:296-305.
37. Gyorffy S., Rodriguez-Lecompte J.C., Woods J.P., Foley R., Kruth S., Liaw P.C., Gauldie J. Bone marrow-derived dendritic cell vaccination of dogs with naturally occurring melanoma by using human gp100 antigen. Journal of Veterinary Internal Medicine 2005, 19:56-63.
38. Hafeman S., London C., Elmslie R., Dow S. Evaluation of liposomal clodronate for treatment of malignant histiocytosis in dogs. Cancer Immunology, Immunotherapy 2010, 59:441-452.
39. Harris C., Pierce K., King G., Yates K.M., Hall J., Tizard I. Efficacy of acemannan in treatment of canine and feline spontaneous neoplasms. Molecular Biotherapy 1991, 3:207-213.
40. Heinzerling L.M., Feige K., Rieder S., Akens M.K., Dummer R., Stranzinger G., Moelling K. Tumor regression induced by intratumoral injection of DNA coding for human interleukin 12 into melanoma metastases in gray horses. Journal of Molecular Medicine 2001, 78:692-702.
41. Henick B.S., Herbst R.S., Goldberg S.B. The PD-1 pathway as a therapeutic target to overcome immune escape mechanisms in cancer. Expert Opinion on Therapeutic Targets 2014, 1-14.
42. Hiraoka K., Zenmyo M., Watari K., Iguchi H., Fotovati A., Kimura Y.N., Hosoi F., Shoda T., Nagata K., Osada H., et al. Inhibition of bone and muscle metastases of lung cancer cells by a decrease in the number of monocytes/macrophages. Cancer Science 2008, 99:1595-1602.
43. Hodi F.S., O'Day S.J., McDermott D.F., Weber R.W., Sosman J.A., Haanen J.B., Gonzalez R., Robert C., Schadendorf D., Hassel J.C., et al. Improved survival with ipilimumab in patients with metastatic melanoma. New England Journal of Medicine 2010, 363:711-723.
44. Hogge G.S., Burkholder J.K., Culp J., Albertini M.R., Dubielzig R.R., Yang N.S., MacEwen E.G. Preclinical development of human granulocyte-macrophage colony-stimulating factor-transfected melanoma cell vaccine using established canine cell lines and normal dogs. Cancer Gene Therapy 1999, 6:26-36.
45. Huang B., Pan P.Y., Li Q., Sato A.I., Levy D.E., Bromberg J., Divino C.M., Chen S.H. Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Research 2006, 66:1123-1131.
46. Huang B., Lei Z., Zhao J., Gong W., Liu J., Chen Z., Liu Y., Li D., Yuan Y., Zhang G.M., et al. CCL2/CCR2 pathway mediates recruitment of myeloid suppressor cells to cancers. Cancer Letters 2007, 252:86-92.
47. Jager E., Ringhoffer M., Karbach J., Arand M., Oesch F., Knuth A. Inverse relationship of melanocyte differentiation antigen expression in melanoma tissues and CD8+ cytotoxic-T-cell responses: Evidence for immunoselection of antigen-loss variants in vivo. International Journal of Cancer 1996, 66:470-476.
48. Jeglum K.A., Young K.M., Barnsley K., Whereat A., McGrath D., Hutson C. Intralymphatic autochthonous tumor cell vaccine in canine lymphoma. Journal of Biological Response Modifiers 1986, 5:168-175.
49. Jin H.T., Ahmed R., Okazaki T. Role of PD-1 in regulating T-cell immunity. Current Topics in Microbiology and Immunology 2011, 350:17-37.
50. Kamstock D., Guth A., Elmslie R., Kurzman I., Liggitt D., Coro L., Fairman J., Dow S. Liposome-DNA complexes infused intravenously inhibit tumor angiogenesis and elicit antitumor activity in dogs with soft tissue sarcoma. Cancer Gene Therapy 2006, 13:306-317.
51. Kamstock D., Elmslie R., Thamm D., Dow S. Evaluation of a xenogeneic VEGF vaccine in dogs with soft tissue sarcoma. Cancer Immunology, Immunotherapy 2007, 56:1299-1309.
52. Kawano M., Itonaga I., Iwasaki T., Tsumura H. Enhancement of antitumor immunity by combining anti-cytotoxic T lymphocyte antigen-4 antibodies and cryotreated tumor lysate-pulsed dendritic cells in murine osteosarcoma. Oncology Reports 2013, 29:1001-1006.
53. Kershaw M.H., Westwood J.A., Slaney C.Y., Darcy P.K. Clinical application of genetically modified T cells in cancer therapy. Clinical and Translational Immunology 2014, 3:e16.
54. Klein M.K. Multimodality therapy for head and neck cancer. The Veterinary Clinics of North America. Small Animal Practice 2003, 33:615-628.
55. Klein W.R., Rutten V.P., Steerenberg P.A., Ruitenberg E.J. The present status of BCG treatment in the veterinary practice. In Vivo 1991, 5:605-608.
56. Kochenderfer J.N., Dudley M.E., Feldman S.A., Wilson W.H., Spaner D.E., Maric I., Stetler-Stevenson M., Phan G.Q., Hughes M.S., Sherry R.M., et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 2012, 119:2709-2720.
57. Kono K. Current status of cancer immunotherapy. Journal of Stem Cells and Regenerative Medicine 2014, 10:8-13.
58. Krummel M.F., Allison J.P. CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells. The Journal of Experimental Medicine 1996, 183:2533-2540.
59. Kurzman I.D., MacEwen E.G., Rosenthal R.C., Fox L.E., Keller E.T., Helfand S.C., Vail D.M., Dubielzig R.R., Madewell B.R., Rodriguez C.O., et al. Adjuvant therapy for osteosarcoma in dogs: Results of randomized clinical trials using combined liposome-encapsulated muramyl tripeptide and cisplatin. Clinical Cancer Research 1995, 1:1595-1601.
60. Lameris R., de Bruin R.C., Schneiders F.L., van Bergen En Henegouwen P.M., Verheul H.M., de Gruijl T.D., van der Vliet H.J. Bispecific antibody platforms for cancer immunotherapy. Critical Reviews in Oncology/Hematology 2014, 92:153-165.
61. Lebbe C., Weber J.S., Maio M., Neyns B., Harmankaya K., Hamid O., O'Day S.J., Konto C., Cykowski L., McHenry M.B., et al. Survival follow-up and ipilimumab retreatment for patients with advanced melanoma who received ipilimumab in prior phase II studies. Annals of Oncology 2014, 25:2277-2284.
62. Li X., Kostareli E., Suffner J., Garbi N., Hammerling G.J. Efficient Treg depletion induces T-cell infiltration and rejection of large tumors. European Journal of Immunology 2010, 40:3325-3335.
63. Liang S.C., Moskalenko M., Van Roey M., Jooss K. Depletion of regulatory T cells by targeting folate receptor 4 enhances the potency of a GM-CSF-secreting tumor cell immunotherapy. Clinical Immunology 2013, 148:287-298.
64. Liao J.C., Gregor P., Wolchok J.D., Orlandi F., Craft D., Leung C., Houghton A.N., Bergman P.J. Vaccination with human tyrosinase DNA induces antibody responses in dogs with advanced melanoma. Cancer Immunity 2006, 6:8.
65. Ma Y., Aymeric L., Locher C., Mattarollo S.R., Delahaye N.F., Pereira P., Boucontet L., Apetoh L., Ghiringhelli F., Casares N., et al. Contribution of IL-17-producing gamma delta T cells to the efficacy of anticancer chemotherapy. Journal of Experimental Medicine 2011, 208:491-503.
66. Ma Y., Mattarollo S.R., Adjemian S., Yang H., Aymeric L., Hannani D., Portela Catani J.P., Duret H., Teng M.W., Kepp O., et al. CCL2/CCR2-dependent recruitment of functional antigen-presenting cells into tumors upon chemotherapy. Cancer Research 2014, 74:436-445.
67. MacEwen E.G. An immunologic approach to the treatment of cancer. The Veterinary Clinics of North America 1977, 7:65-75.
68. MacEwen E.G. Approaches to cancer therapy using biological response modifiers. The Veterinary Clinics of North America. Small Animal Practice 1985, 15:667-688.
69. MacEwen E.G., Patnaik A.K., Harvey H.J., Hayes A.A., Matus R. Canine oral melanoma: Comparison of surgery versus surgery plus Corynebacterium parvum. Cancer Investigation 1986, 4:397-402.
70. MacEwen E.G., Kurzman I.D., Vail D.M., Dubielzig R.R., Everlith K., Madewell B.R., Rodriguez C.O., Phillips B., Zwahlen C.H., Obradovich J., et al. Adjuvant therapy for melanoma in dogs: Results of randomized clinical trials using surgery, liposome-encapsulated muramyl tripeptide, and granulocyte macrophage colony-stimulating factor. Clinical Cancer Research 1999, 5:4249-4258.
71. Maekawa N., Konnai S., Ikebuchi R., Okagawa T., Adachi M., Takagi S., Kagawa Y., Nakajima C., Suzuki Y., Murata S., et al. Expression of PD-L1 on canine tumor cells and enhancement of IFN-gamma production from tumor-infiltrating cells by PD-L1 blockade. PLoS ONE 2014, 9:e98415.
72. Maleki L.A., Baradaran B., Majidi J., Mohammadian M., Shahneh F.Z. Future prospects of monoclonal antibodies as magic bullets in immunotherapy. Human Antibodies 2013, 22:9-13.
73. Marconato L., Frayssinet P., Rouquet N., Comazzi S., Leone V.F., Laganga P., Rossi F., Vignoli M., Pezzoli L., Aresu L. Randomized, placebo-controlled, double-blinded chemoimmunotherapy clinical trial in a pet dog model of diffuse large B-cell lymphoma. Clinical Cancer Research 2014, 20:668-677.
74. Mata M., Vera J.F., Gerken C., Rooney C.M., Miller T., Pfent C., Wang L.L., Wilson-Robles H.M., Gottschalk S. Toward immunotherapy with redirected T cells in a large animal model: Ex vivo activation, expansion, and genetic modification of canine T cells. Journal of Immunotherapy 2014, 37:407-415.
75. McCormack E., Adams K.J., Hassan N.J., Kotian A., Lissin N.M., Sami M., Mujic M., Osdal T., Gjertsen B.T., Baker D., et al. Bi-specific TCR-anti CD3 redirected T-cell targeting of NY-ESO-1- and LAGE-1-positive tumors. Cancer Immunology, Immunotherapy 2013, 62:773-785.
76. McDermott D.F., Atkins M.B. PD-1 as a potential target in cancer therapy. Cancer Medicine 2013, 2:662-673.
77. Merelli B., Massi D., Cattaneo L., Mandala M. Targeting the PD1/PD-L1 axis in melanoma: Biological rationale, clinical challenges and opportunities. Critical Reviews in Oncology/Hematology 2014, 89:140-165.
78. Miller M.J., Foy K.C., Kaumaya P.T. Cancer immunotherapy: Present status, future perspective, and a new paradigm of peptide immunotherapeutics. Discovery Medicine 2013, 15:166-176.
79. Miselis N.R., Wu Z.J., Van Rooijen N., Kane A.B. Targeting tumor-associated macrophages in an orthotopic murine model of diffuse malignant mesothelioma. Molecular Cancer Therapeutics 2008, 7:788-799.
80. Mitchell L., Thamm D.H., Biller B.J. Clinical and immunomodulatory effects of toceranib combined with low-dose cyclophosphamide in dogs with cancer. Journal of Veterinary Internal Medicine 2012, 26:355-362.
81. Mitchell L.A., Henderson A.J., Dow S.W. Suppression of vaccine immunity by inflammatory monocytes. Journal of Immunology 2012, 189:5612-5621.
82. Mitchell L.A., Hansen R.J., Beaupre A.J., Gustafson D.L., Dow S.W. Optimized dosing of a CCR2 antagonist for amplification of vaccine immunity. International Immunopharmacology 2013, 15:357-363.
83. Mito K., Sugiura K., Ueda K., Hori T., Akazawa T., Yamate J., Nakagawa H., Hatoya S., Inaba M., Inoue N., et al. IFN markedly cooperates with intratumoral dendritic cell vaccine in dog tumor models. Cancer Research 2010, 70:7093-7101.
84. Mukaratirwa S., Chitanga S., Chimatira T., Makuleke C., Sayi S.T., Bhebhe E. Combination therapy using intratumoral bacillus Calmette-Guerin (BCG) and vincristine in dogs with transmissible venereal tumours: Therapeutic efficacy and histological changes. Journal of the South African Veterinary Association 2009, 80:92-96.
85. Muller D., Kontermann R.E. Bispecific antibodies for cancer immunotherapy: Current perspectives. Biodrugs: Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy 2010, 24:89-98.
86. O'Connor C.M., Wilson-Robles H. Developing T cell cancer immunotherapy in the dog with lymphoma. ILAR Journal 2014, 55:169-181.
87. O'Neill K., Guth A., Biller B., Elmslie R., Dow S. Changes in regulatory T cells in dogs with cancer and associations with tumor type. Journal of Veterinary Internal Medicine 2009, 23:875-881.
88. Ostrand-Rosenberg S. Myeloid-derived suppressor cells: More mechanisms for inhibiting antitumor immunity. Cancer Immunology, Immunotherapy 2010, 59:1593-1600.
89. Ostrand-Rosenberg S., Sinha P. Myeloid-derived suppressor cells: Linking inflammation and cancer. Journal of Immunology 2009, 182:4499-4506.
90. Ott P.A., Hodi F.S., Robert C. CTLA-4 and PD-1/PD-L1 blockade: New immunotherapeutic modalities with durable clinical benefit in melanoma patients. Clinical Cancer Research 2013, 19:5300-5309.
91. Ottnod J.M., Smedley R.C., Walshaw R., Hauptman J.G., Kiupel M., Obradovich J.E. A retrospective analysis of the efficacy of Oncept vaccine for the adjunct treatment of canine oral malignant melanoma. Veterinary and Comparative Oncology 2013, 11:219-229.
92. Pai C.C., Kuo T.F., Mao S.J., Chuang T.F., Lin C.S., Chu R.M. Immunopathogenic behaviors of canine transmissible venereal tumor in dogs following an immunotherapy using dendritic/tumor cell hybrid. Veterinary Immunology and Immunopatholology 2011, 139:187-199.
93. Parodi A.L., Misdorp W., Mialot J.P., Mialot M., Hart A.A., Hurtrel M., Salomon J.C. Intratumoral BCG and Corynebacterium parvum therapy of canine mammary tumours before radical mastectomy. Cancer Immunology and Immunotherapy 1983, 15:172-177.
94. Pavlin D., Cemazar M., Cor A., Sersa G., Pogacnik A., Tozon N. Electrogene therapy with interleukin-12 in canine mast cell tumors. Radiology Oncology 2011, 45:31-39.
95. Penzo C., Ross M., Muirhead R., Else R., Argyle D.J. Effect of recombinant feline interferon-omega alone and in combination with chemotherapeutic agents on putative tumour-initiating cells and daughter cells derived from canine and feline mammary tumours. Veterinary and Comparative Oncology 2009, 7:222-229.
96. Perez-Gracia J.L., Labiano S., Rodriguez-Ruiz M.E., Sanmamed M.F., Melero I. Orchestrating immune check-point blockade for cancer immunotherapy in combinations. Current Opinion in Immunology 2014, 27:89-97.
97. Peruzzi D., Gavazza A., Mesiti G., Lubas G., Scarselli E., Conforti A., Bendtsen C., Ciliberto G., La Monica N., Aurisicchio L. A vaccine targeting telomerase enhances survival of dogs affected by B-cell lymphoma. Molecular Therapy 2010, 18:1559-1567.
98. Pluhar G.E., Grogan P.T., Seiler C., Goulart M., Santacruz K.S., Carlson C., Chen W., Olin M.R., Lowenstein P.R., Castro M.G., et al. Anti-tumor immune response correlates with neurological symptoms in a dog with spontaneous astrocytoma treated by gene and vaccine therapy. Vaccine 2010, 28:3371-3378.
99. Pol J., Bloy N., Obrist F., Eggermont A., Galon J., Herve Fridman W., Cremer I., Zitvogel L., Kroemer G., Galluzzi L. Trial Watch: DNA vaccines for cancer therapy. Oncoimmunology 2014, 3:e28185.
100. Poole R.M. Pembrolizumab: first global approval. Drugs 2014, 74:1973-1981.
101. Quezada S.A., Peggs K.S. Exploiting CTLA-4, PD-1 and PD-L1 to reactivate the host immune response against cancer. British Journal of Cancer 2013, 108:1560-1565.
102. Raval R.R., Sharabi A.B., Walker A.J., Drake C.G., Sharma P. Tumor immunology and cancer immunotherapy: Summary of the 2013 SITC primer. Journal for Immunotherapy of Cancer 2014, 2:14.
103. Reed S.D., Fulmer A., Buckholz J., Zhang B., Cutrera J., Shiomitsu K., Li S. Bleomycin/interleukin-12 electrochemogene therapy for treating naturally occurring spontaneous neoplasms in dogs. Cancer Gene Therapy 2010, 17:457-464.
104. Restifo N.P., Dudley M.E., Rosenberg S.A. Adoptive immunotherapy for cancer: Harnessing the T cell response. Nature Reviews. Immunology 2012, 12:269-281.
105. Riches J.C., Gribben J.G. Advances in chimeric antigen receptor immunotherapy for chronic lymphocytic leukemia. Discovery Medicine 2013, 16:295-302.
106. Riley J.L. Combination checkpoint blockade-taking melanoma immunotherapy to the next level. The New England Journal of Medicine 2013, 369:187-189.
107. Rissetto K.C., Rindt H., Selting K.A., Villamil J.A., Henry C.J., Reinero C.R. Cloning and expression of canine CD25 for validation of an anti-human CD25 antibody to compare T regulatory lymphocytes in healthy dogs and dogs with osteosarcoma. Veterinary Immunology and Immunopathology 2010, 135:137-145.
108. Robbins P.F., Morgan R.A., Feldman S.A., Yang J.C., Sherry R.M., Dudley M.E., Wunderlich J.R., Nahvi A.V., Helman L.J., Mackall C.L., et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. Journal of Clinical Oncology 2011, 29:917-924.
109. Robbins P.F., Kassim S.H., Tran T.L., Crystal J.S., Morgan R.A., Feldman S.A., Yang J.C., Dudley M.E., Wunderlich J.R., Sherry R.M., et al. A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: Long-term follow-up and correlates with response. Clinical Cancer Research 2015, 21:1019-1027.
110. Robert C., Soria J.C., Eggermont A.M. Drug of the year: Programmed death-1 receptor/programmed death-1 ligand-1 receptor monoclonal antibodies. European Journal of Cancer 2013, 49:2968-2971.
111. Rosales C., Jeglum K.A., Obrocka M., Steplewski Z. Cytolytic activity of murine anti-dog lymphoma monoclonal antibodies with canine effector cells and complement. Cellular Immunology 1988, 115:420-428.
112. Ruffell B., Affara N.I., Coussens L.M. Differential macrophage programming in the tumor microenvironment. Trends in Immunology 2012, 33:119-126.
113. Sakuishi K., Apetoh L., Sullivan J.M., Blazar B.R., Kuchroo V.K., Anderson A.C. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. The Journal of Experimental Medicine 2010, 207:2187-2194.
114. Sanlorenzo M., Vujic I., Posch C., Dajee A., Yen A., Kim S., Ashworth M., Rosenblum M.D., Algazi A., Osella-Abate S., et al. Melanoma immunotherapy. Cancer Biology and Therapy 2014, 15:665-674.
115. Shin J.H., Park H.B., Oh Y.M., Lim D.P., Lee J.E., Seo H.H., Lee S.J., Eom H.S., Kim I.H., Lee S.H., et al. Positive conversion of negative signaling of CTLA4 potentiates antitumor efficacy of adoptive T-cell therapy in murine tumor models. Blood 2012, 119:5678-5687.
116. Siddiqui F., Li C.Y., Larue S.M., Poulson J.M., Avery P.R., Pruitt A.F., Zhang X., Ullrich R.L., Thrall D.E., Dewhirst M.W., et al. A phase I trial of hyperthermia-induced interleukin-12 gene therapy in spontaneously arising feline soft tissue sarcomas. Molecular Cancer Therapeutics 2007, 6:380-389.
117. Sinha P., Clements V.K., Bunt S.K., Albelda S.M., Ostrand-Rosenberg S. Cross-talk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response. Journal of Immunology 2007, 179:977-983.
118. Sliwkowski M.X., Mellman I. Antibody therapeutics in cancer. Science 2013, 341:1192-1198.
119. Son C.H., Bae J.H., Shin D.Y., Lee H.R., Choi Y.J., Jo W.S., Ho Jung M., Kang C.D., Yang K., Park Y.S. CTLA-4 blockade enhances antitumor immunity of intratumoral injection of immature dendritic cells into irradiated tumor in a mouse colon cancer model. Journal of Immunotherapy 2014, 37:1-7.
120. Sorenmo K.U., Krick E., Coughlin C.M., Overley B., Gregor T.P., Vonderheide R.H., Mason N.J. CD40-activated B cell cancer vaccine improves second clinical remission and survival in privately owned dogs with non-Hodgkin's lymphoma. PLoS ONE 2011, 6:e24167.
121. Srivastava M.K., Sinha P., Clements V.K., Rodriguez P., Ostrand-Rosenberg S. Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine. Cancer Research 2010, 70:68-77.
122. Stroncek D.F., Berger C., Cheever M.A., Childs R.W., Dudley M.E., Flynn P., Gattinoni L., Heath J.R., Kalos M., Marincola F.M., et al. New directions in cellular therapy of cancer: A summary of the summit on cellular therapy for cancer. Journal of Translational Medicine 2012, 10:48.
123. Talmadge J.E., Gabrilovich D.I. History of myeloid-derived suppressor cells. Nature Reviews. Cancer 2013, 13:739-752.
124. Tamura K., Yamada M., Isotani M., Arai H., Yagihara H., Ono K., Washizu T., Bonkobara M. Induction of dendritic cell-mediated immune responses against canine malignant melanoma cells. The Veterinary Journal 2008, 175:126-129.
125. Tan C., Reddy V., Dannull J., Ding E., Nair S.K., Tyler D.S., Pruitt S.K., Lee W.T. Impact of anti-CD25 monoclonal antibody on dendritic cell-tumor fusion vaccine efficacy in a murine melanoma model. Journal of Translational Medicine 2013, 11:148.
126. Topalian S.L., Drake C.G., Pardoll D.M. Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Current Opinion in Immunology 2012, 24:207-212.
127. Turek M., Padilla M., Argyle D.J. Evaluation of the gene for inducible nitric oxide synthase as a radiosensitizer under hypoxic and oxic conditions. Veterinary and Comparative Oncology 2007, 5:250-255.
128. Tzannes S., Ibarrola P., Batchelor D.J., Burrow R.D., Blackwood L. Use of recombinant human interferon alpha-2a in the management of a dog with epitheliotropic lymphoma. Journal of the American Animal Hospital Association 2008, 44:276-282.
129. U'Ren L.W., Biller B.J., Elmslie R.E., Thamm D.H., Dow S.W. Evaluation of a novel tumor vaccine in dogs with hemangiosarcoma. Journal of Veterinary Internal Medicine 2007, 21:113-120.
130. Vail D.M., MacEwen E.G., Kurzman I.D., Dubielzig R.R., Helfand S.C., Kisseberth W.C., London C.A., Obradovich J.E., Madewell B.R., Rodriguez C.O., et al. Liposome-encapsulated muramyl tripeptide phosphatidylethanolamine adjuvant immunotherapy for splenic hemangiosarcoma in the dog: A randomized multi-institutional clinical trial. Clinical Cancer Research 1995, 1:1165-1170.
131. Woo S.R., Turnis M.E., Goldberg M.V., Bankoti J., Selby M., Nirschl C.J., Bettini M.L., Gravano D.M., Vogel P., Liu C.L., et al. Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Research 2012, 72:917-927.
132. Wu Y.L., Liang J., Zhang W., Tanaka Y., Sugiyama H. Immunotherapies: The blockade of inhibitory signals. International Journal of Biological Sciences 2012, 8:1420-1430.
133. Zeisberger S.M., Odermatt B., Marty C., Zehnder-Fjallman A.H., Ballmer-Hofer K., Schwendener R.A. Clodronate-liposome-mediated depletion of tumour-associated macrophages: A new and highly effective antiangiogenic therapy approach. British Journal of Cancer 2006, 95:272-281.
134. Zhang L., Tizard I.R. Activation of a mouse macrophage cell line by acemannan: The major carbohydrate fraction from Aloe vera gel. Immunopharmacology 1996, 35:119-128.
135. Zhang W., Zhu X.D., Sun H.C., Xiong Y.Q., Zhuang P.Y., Xu H.X., Kong L.Q., Wang L., Wu W.Z., Tang Z.Y. Depletion of tumor-associated macrophages enhances the effect of sorafenib in metastatic liver cancer models by antimetastatic and antiangiogenic effects. Clinical Cancer Research 2010, 16:3420-3430.
136. Zhao L., Lim S.Y., Gordon-Weeks A.N., Tapmeier T.T., Im J.H., Cao Y., Beech J., Allen D., Smart S., Muschel R.J. Recruitment of a myeloid cell subset (CD11b/Gr1 mid) via CCL2/CCR2 promotes the development of colorectal cancer liver metastasis. Hepatology 2013, 57:829-839.
137. Zhou L., Xu N., Sun Y., Liu X.M. Targeted biopharmaceuticals for cancer treatment. Cancer Letters 2014, 352:145-151.
138. Zigler M., Shir A., Levitzki A. Targeted cancer immunotherapy. Current Opinion in Pharmacology 2013, 13:504-510.